The function of the pro-apoptotic molecule BAD is regulated by phosphorylation of two sites, serine-112 (Ser-112) and . Phosphorylation at either site results in loss of the ability of BAD to heterodimerize with the survival proteins BCL-X L or BCL-2. Phosphorylated BAD binds to 14-3-3 and is sequestered in the cytoplasm. It has been shown that phosphorylation of BAD at Ser-136 is mediated by the serine/threonine protein kinase Akt-1/PKB which is downstream of phosphatidylinositol 3-kinase (PI3K). The signaling process leading to phosphorylation of BAD at Ser-112 has not been identi®ed. In this study, we show that phosphorylation of the two serine residues of BAD is dierentially regulated. While Ser-136 phosphorylation is concordant with activation of Akt, Ser-112 phosphorylation does not correlate with Akt activation. Instead, we demonstrate that activated Ras and Raf, which are upstream of mitogen-activated protein kinases (MAPK), stimulate selective phosphorylation of BAD at Ser-112. Furthermore, phosphorylation of Ser-112, but not Ser-136 requires activation of the MAPK pathway as the MEK inhibitor, PD 98059, blocks EGF-, as well as activated Ras-or Raf-mediated phosphorylation of BAD at Ser-112. Therefore, the PI3K-Akt and Ras-MAPK pathways converge at BAD by mediating phosphorylation of distinct serine residues.
Introduction
Proteins of the BCL-2 family are critical regulators of cell death in mammalian cells (White, 1996) . BAD, a distant member of the BCL-2 family, exerts its deathpromoting eect by hetero-dimerizing with BCL-X L and BCL-2 death antagonists in the mitochondria . BAD is phosphorylated on serine residues in response to stimulation with survival factors such as platelet-derived growth factor (PDGF) and interleukin-3 (IL-3) (Zha et al., 1996; del Peso et al., 1997; Datta et al., 1997) . Upon phosphorylation, BAD dissociates from BCL-X L and is bound and sequestered in the cytoplasm by the tau form of 14-3-3 proteins (Zha et al., 1996) . Thus, the kinases mediating BAD phosphorylation are key players in the regulation of cell survival. Two groups have recently presented evidence that Akt-1/PKB, a serine/threonine protein kinase downstream of phosphatidylinositol 3-kinase (PI3K) binds to and phosphorylates BAD (del Peso et al., 1997; Datta et al., 1997) . Identi®cation of the PI3K-Akt-BAD pathway provides a link between the survival eect of cytokines and a component of the cell-intrinsic death machinery.
Previous experiments established that there are two phosphorylation sites that regulate the binding properties of BAD, Ser-112 (RSRHSpSYP) and Ser-136 (RQRSTpSTP) (Zha et al., 1996) . Phosphorylation of either site has been shown to prevent BAD from heterodimerizing with BCL-X L (Zha et al., 1996) . Only Ser-136 has been demonstrated to be a target of Akt (Datta et al., 1997) . Although the Ser-112 site also conforms with the de®ned RXRXXS Akt consensus sequence (Zha et al., 1996; del Peso et al., 1997) , the kinase(s) and signaling cascade(s) regulating Ser-112 phosphorylation have not been identi®ed. Further, at least in vitro, PKC and Raf-1 do not directly phosphorylate either Ser-112 or Ser-136 of BAD (Zha et al., 1996; Datta et al., 1997) .
Like many other critical mediators, BAD is apparently phosphorylated by mechanisms involving more than one signaling module. For example, Raf-1, when tethered to the mitochondria membrane, prevents apoptosis and concurrently induces BAD phosphorylation (Wang et al., 1996; Salomoni et al., 1998) , suggesting a Raf-mediated pathway leading to BAD phosphorylation. However, the speci®c site of phosphorylation and the mechanism involved are unknown. There is no evidence that Raf exerts its eect through the PI3K-Akt module. Further evidence for a PI3K-Akt-independent route to BAD phosphorylation is provided by the observation that, in hemopoietic cells, granulocyte/macrophage colony stimulating factor (GM-CSF) induces BAD phosphorylation without inducing detectable activation of Akt (Scheid and Duronio, 1998) . Instead, BAD phosphorylation upon stimulation with cytokines seems to correlate with and depend on MEK activity. However, these previous studies, which used gel-mobility-shift analysis to detect phosphorylation of BAD, did not identify which site, Ser-112, Ser-136 or other residues on BAD, was phosphorylated upon stimulation.
In the current study using phosphorylation sitespeci®c antibodies, we have dissected the signaling events leading to BAD phosphorylation at individual sites . We herein present evidence that phosphorylation of the two regulatory serine residues of BAD is dierentially regulated in response to growth factors. While Ser-136 phosphorylation appears concordant with activation of Akt, Ser-112 phosphorylation does not correlate with Akt activation. We demonstrate that growth factor-mediated phosphorylation of BAD at Ser-112, but not Ser-136, is regulated by the Ras-mitogen-activated protein kinase (MAPK) pathway. Activated forms of Ras or Raf, upstream of MAPK (Cowley et al., 1994) , stimulate selective phosphorylation of BAD at Ser-112 in a MEK-dependent manner. Therefore, phosphorylation of BAD at Ser-112 appears to lie downstream of the Ras-MAPK cascade.
Results
Phosphorylation of BAD at Ser-112 and Ser-136 is dierentially regulated Availability of phosphorylation site-speci®c BAD antibodies allows direct examination of BAD phosphorylation at speci®c serine residues upon stimulation with growth/survival factors. In a number of cell lines including HEK293 and Swiss 3T3, however, these antibodies were not suciently sensitive to detect phosphorylated BAD by Western analysis (data not shown). This could be due either to a weak reactivity of the antibodies or to low expression of the endogenous proapoptotic BAD protein in most cultured cell types. To circumvent this diculty, HEK293 cells were transiently transfected with a BAD expression vector in which the murine BAD cDNA was linked to the Flag M2 epitope tag (pcDNA3.1-Flag-BAD) (del Peso et al., 1997). Following serum starvation, the transfected cells were stimulated with platelet-derived growth factor (PDGF), insulin-like growth factor-I (IGF-I), epidermal growth factor (EGF) or insulin. We were unable to detect a signi®cant response to PDGF (data not shown) probably because of the lack of functional PDGF receptors in HEK293 cells. Upon stimulation with IGF-I, EGF or insulin, phosphorylation of BAD at Ser-136 was detected with the response to IGF-I and insulin being stronger than the eect of EGF ( Figure  1 ). In contrast, under the same conditions, EGF provided a much more potent stimulus for phosphorylation of Ser-112. Insulin, in spite of stimulating signi®cant phosphorylation of Ser-136, induced little increase, if any, in Ser-112 phosphorylation. Thus, growth factor-induced phosphorylation of the two serine residues of BAD is dissociable and likely regulated by independent mechanisms.
As phosphorylation of Ser-136 of BAD has been shown to be mediated by Akt (Datta et al., 1997) , we assessed Akt phosphorylation status in cells stimulated by EGF, IGF-I or insulin. Since Akt is activated through phosphorylation at Ser-473 and Thr-308 (Alessi et al., 1996) , measuring phosphorylation of these sites utilizing phospho-speci®c antibodies oers a surrogate index for Akt activation in intact cells. In response to IGF-I or insulin, abundant and sustained phosphorylation at both Ser-473 and Thr-308 was readily detected (Figure 1 ). Therefore the failure of insulin to stimulate phosphorylation of BAD at Ser-112 was not due to a lack of Akt activation. Consistent with previous studies in NIH3T3 ®broblasts (Franke et al., 1995) , EGF is a weak activator of Akt in HEK293 cells in that it induced only limited and transient phosphorylation of Akt, particularly at Thr-308, in contrast to strong and sustained phosphorylation of BAD at Ser-112 ( Figure 1 ). The results indicate that phosphorylation of BAD at Ser-112 does not correlate with Akt activation.
In an attempt to further explore the role of Akt in phosphorylation of BAD, we co-stimulated HEK293 cells with EGF and insulin, two factors exhibiting dierential eects on phosphorylation of Ser-112 and Ser-136 of BAD ( Figure 2 ). As described above, insulin was a strong activator of Akt while EGF was a weak one. In co-stimulated cells, Akt phosphorylation at Ser-473 and Thr-308 was unexpectedly reduced compared with that stimulated by insulin alone (Figure 2 ), suggesting that EGF receptor signaling interferes with insulin-stimulated activation of the PI3K-Akt pathway. Compatible with Akt accounting for phosphorylation of BAD at Ser-136, a concomitant reduction in the level of Ser-136 phosphorylation was observed in the co-stimulated cells. However, the level of Ser-112 phosphorylation of BAD was similar to or slightly higher than that obtained by stimulation with Figure 1 Phosphorylation of BAD at Ser-112 and Ser-136 is dierentially regulated in response to growth factors. After transfection with pcDNA3.1-Flag-BAD and starvation in serum-free medium, HEK293 cells were stimulated with EGF (25 ng/ml), IGF-I (75 ng/ml) or insulin (0.1 mM) for the indicated periods of time (minutes). Phosphorylation of transfected Flag-BAD at Ser-136 and Ser-112 and phosphorylation of the endogenous Akt at Ser-473 and Thr-308 were examined by Western blot analysis using phospho-speci®c antibodies as described in Materials and methods. Reprobing with antibodies against Flag M2 and b-actin is included to show comparable expression levels of Flag-BAD and similar loading among samples EGF alone (Figure 2) . Therefore, the attenuation of Akt activity was accompanied by down-regulation of BAD phosphorylation at Ser-136 only, further suggesting that Akt is not the primary mediator of Ser-112 phosphorylation.
BAD phosphorylation at Ser-112 correlates with activation of MAPK
To elucidate the mechanism regulating phosphorylation of BAD at Ser-112, we assessed the potential role of the Ras-MAPK pathway. The Ras-MAPK signaling pathway is essential for cell proliferation and differentiation (Cowley et al., 1994) . It also plays an important role in the regulation of cell survival (Xia et al., 1995; Gardner and Johnson, 1996; Parrizas et al., 1997; Bergmann et al., 1998) . MAPK activity was examined in HEK293 cells stimulated with EGF, IGF-I or insulin using a phospho-speci®c antibody and by means of gel-mobility shift assays. As shown in Figure  3 , the magnitude of MAPK (Erk1 and Erk2) phosphorylation and that of BAD phosphorylation at Ser-112, but not Ser-136, were concordant. For instance, EGF, which was most ecient at inducing Ser-112 phosphorylation of BAD, generated the strongest phosphorylation of Erk1 and Erk2. Insulin, a poor inducer of Ser-112 phosphorylation of BAD, 
Activated forms of Ras and Raf stimulate Ser-112, but not Ser-136, phosphorylation
If EGF-induced BAD Ser-112 phosphorylation is mediated by the Ras-MAPK pathway, activation of MAPK by expression of dominantly positive forms of the upstream regulators should stimulate phosphorylation of BAD speci®cally at Ser-112. To address this possibility, HEK293 cells were cotransfected with pcDNA3.1-Flag-BAD and a construct expressing cHa-Ras (wild type or V12 mutant) (Fang et al., 1992) , activated Raf-1 (Bruder et al., 1992) or empty vectors. As shown in Figure 4 , expression of the constitutively activated Ras or Raf greatly enhanced BAD phosphorylation at Ser-112. As expected, expression of these active forms of Ras and Raf also strongly activate MAPK in transfected cells (data not shown). However, the activated Ras or Raf did not increase the level of phosphorylation of BAD at Ser-136 (Figure 4) , demonstrating speci®city for Ser-112. As a control, expression of constitutively active form of Rac, which activates the c-Jun N-terminal kinase (JNK) but not Erk (Coso et al., 1995) , did not stimulate BAD phosphorylation at either site (data not shown). The results indicate that activation of the Ras-MAPK pathway is sucient to induce speci®c phosphorylation of BAD at Ser-112.
MEK activity is required for ligand-and Ras/Raf-stimulated BAD phosphorylation at Ser-112
The correlation of MAPK activity with BAD Ser-112 phosphorylation prompted us to ask whether MAPK activity is required for ligand-induced BAD phosphorylation at Ser-112. HEK293 cells were treated with a MEK inhibitor PD 98059, which has been shown to speci®cally inhibit growth factor-induced MAPK activation in a wide range of cell lines (Dudley et al., 1995) . As expected, treatment of HEK293 cells with PD 98059 resulted in a dosage-dependent decrease in EGF-induced MAPK phosphorylation (Figure 5a,b) . Consistent with a causal role of MEK and likely MAPK activity in the induction of BAD Ser-112 phosphorylation, PD 98059 induced a dose-dependent inhibition of EGF-mediated BAD phosphorylation at Ser-112 (Figure 5b ). In contrast, phosphorylation of Ser-136 of BAD and of Akt was not decreased by PD 98059. In fact, due to an as yet unde®ned mechanism, treatment with PD 98059 led to some potentiation of Akt and BAD Ser-136 phosphorylation. As a control, treatment with the p70 S6 kinase inhibitor, rapamycin (Chung et al., 1992) did not aect phosphorylation of either Ser-112 or Ser-136 (Figure 5a ). The speci®c eect of the MEK inhibitor on ligand-mediated phosphorylation of BAD at Ser-112 supports the contention that We next examined the eect of PD 98059 on activated Ras or Raf-stimulated BAD Ser-112 phosphorylation. Figure 5c demonstrated that treatment of transfected cells with PD 98059 blocked Raf-mediated induction of BAD phosphorylation at Ser-112 with no eect on Ser-136 phosphorylation. PD 98059 also inhibited activated Ras-mediated Ser-112 phosphorylation (data not shown). These results con®rm that Ras and Raf stimulate phosphorylation of BAD via a MEK-dependent process.
Discussion
Previous results employing mutant IGF-I receptors and inhibitors of PI3K suggest that the PI3K signaling cascade is a potent regulator of cell survival (Harrington et al., 1994; Kulik et al., 1997; Kennedy et al., 1997; Parrizas et al., 1997) . More recent studies have identi®ed the serine/threonine protein kinase Akt/PKB as a downstream target of PI3K (Franke et al., 1995; Burgering and Coer, 1995) , that in turn, phosphorylates the BAD protein altering its association with BCL-X L , BCL-2 and 14-3-3 (del Peso et al., 1997; Datta et al., 1997) . However, a general role for this pathway in cell survival decisions is controversial, as, in certain circumstances, death suppression can be accomplished without activation of Akt/PKB or through a PI3K-independent mechanism (Scheid and Duronio, 1998; Kulik and Weber, 1998; Craddock et al., 1999) . Furthermore, induction of BAD phosphorylation seems to be more complicated than can be explained by Akt/PKB-mediated phosphorylation alone (Wang et al., 1996; Scheid and Duronio, 1998) . In the present report, we have studied the mechanism that regulates phosphorylation of BAD at Ser-112. The data presented herein is most compatible with Ser-112 phosphorylation being downstream of the Ras-MAPK pathway. However, this does not exclude implication of other signaling cascades in the regulation of BAD phosphorylation as a signi®cant basal level of phosphorylation of BAD does not appear to be suppressed by inhibition of either the PKB (del Peso et al., 1997; Datta et al., 1997) or MAPK pathway ( Figure 5 ). The Ras-MAPK cascade may represent only one of the pathways involved in the control of phosphorylation of BAD.
Demonstration of the role of the Ras-MAPK pathway in the stimulation of BAD phosphorylation reveals interaction of the Ras-MAPK pathway with a member of the BCL-2 family. The Ras-MAPK pathway has been shown to promote cell survival in many dierent systems (Xia et al., 1995; Gardner and Johnson, 1996; Parrizas et al., 1997; Kurada and White, 1998; Bergmann et al., 1998) . There has been a lack of functional connection between the Ras-MAPK pathway and a pro-apoptotic molecule or death antagonist of the BCL-2 family although the Ras-MAPK pathway has been shown to down-regulate the proapoptotic activity of the gene head involution defective (hid) (Kurada and White, 1998; Bergmann et al., 1998) . Our results suggest that BAD may not only provide a relay for the antiapoptotic activity of Akt, but also act as a potential eector for MAPKmediated suppression of apoptosis.
The observation that activated forms of Ras and Raf induce phosphorylation or inactivation of BAD may be of particular importance as these oncogenes, especially Ras, are frequently mutated/activated in human cancers (Barbacid, 1987) . It is likely that this eect on the function of BAD may contribute to the oncogenic property of mutated Ras or Raf. Functional activation of the Ras-MAPK pathway in the absence of genetic mutations of Ras or Raf, has been reported in some human cancers (Patton et al., 1998) . Therefore, the abnormal activation of the Ras-MAPK pathway may associate with a larger number of human cancers than would be predicted by Ras mutation alone. It will be of interest to determine whether BAD phosphorylation at Ser-112 is elevated in human cancers or cell lines bearing mutant Ras or those showing functional activation of the Ras-MAPK pathway.
It should be pointed out that our conclusion is drawn from experiments of overexpression of BAD. To further prove the involvement of the MAPK cascade in the control of BAD phosphorylation, it will be necessary to study the eect of EGF and inhibitors of the MAPK pathway on phosphorylation of the endogenous BAD instead of transfected BAD. Finally, although we have established a role for the Ras-MAPK pathway in the modulation of BAD phosphorylation at Ser-112, the kinase speci®cally responsible for phosphorylating this site has not been determined. The substrate speci®city of MEK-1 (Dudley et al., 1995) makes it unlikely that MEK-1 itself functions as a BAD kinase. Erk1 and/or Erk2 may phosphorylate BAD directly or through activation of other kinases such as Rsk-2. Indeed in vitro, Rsk-2 is capable of phosphorylating serine 21 of glycogen synthase kinase3a (GSK-3a) and serine 9 of glycogen synthase kinase3b (GSK-3b) (Southerland et al., 1993; Stambolic and Woodgett, 1994) . The amino acid sequence around these serine residues of GSK-3a and GSK-3b resembles the sequence surrounding Ser-112 of BAD (Zha et al., 1996; del Peso et al., 1997; Datta et al., 1997) .
Materials and methods

Reagents
PD 98059 and rapamycin were purchased from Calbiochem (San Diego, CA, USA). EGF and insulin were obtained from GIBCO/BRL (Gaithersburg, MD, USA). PDGF A/B and IGF-I were from Sigma (St. Louis, MO, USA) and UBI (Lake Placid, NY, USA), respectively. Anti-phospho Akt and anti-phospho BAD antibodies were from New England Biolabs (Beverly, MA, USA). Anti-active MAPK was purchased from Promega (Madison, WI, USA). Anti-Flag M2 monoclonal antibody was from Sigma. Other antibodies used in the study were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The plasmid pcDNA3.1-Flag-BAD (del Peso et al., 1997) was a gift of Dr G NunÄ ez. The Raf-BXB vector (Bruder et al., 1992) was provided by Dr UR Rapp. The V12 Rac1 construct (Coso et al., 1995) was from Dr JS Gutkind. The sources and structures of vectors expressing Ha-Ras were published previously (Fang et al., 1992) .
Cell lines and growth conditions
HEK293 and Swiss 3T3 cells were obtained from American Type Culture Collection (ATCC). The cells were grown in DMEM (GIBCO/BRL) supplemented with 10% fetal bovine serum (FBS) (Sigma). These cell lines were frozen at early passages and used for less than 10 weeks in continuous culture.
Transfection
HEK293 cells were plated in 60-mm dishes. One day later at around 60% con¯uence, the cells were transfected using Fugene 6 according to the protocol of the supplier (Boehringer Mannheim, Indianapolis, IN, USA). In cotransfection experiments, the molar ratio of the BADexpressing plasmid and that of Ras or Raf were adjusted to 1 : 5 to ensure co-expression of Ras or Raf with BAD. Two days after transfection, cells were starved overnight (12 ± 16 h) and then stimulated with ligand or vehicle.
Western blot
Lysates were made from control and stimulated cells in ice cold X-100 lysis buer. Equal amounts of total cellular protein were separated by SDS-polyacylamide gel electrophoresis (SDS ± PAGE), transferred to immobilon (PVDF), and immunoblotted with antibodies following the protocols provided by manufacturers. Immunocomplexes were visualized by an enhanced chemiluminescence (ECL) detection kit (Amersham, Arlington Height, IL, USA) using horse-radish peroxidase-conjugated secondary antibodies (BIO-RAD, Hercules, CA, USA).
Abbreviations EGF, epidermal growth factor; IGF-I, insulin-like growth factor-I; MAPK, mitogen-activated protein kinase; PDGF, platelet-derived growth factor; PI3K, phosphatidylinositol 3-kinase
